Navigation Links
Vasogen Announces First Quarter 2008 Results
Date:4/3/2008

d in this press release, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of the Celacade(TM) System or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of
'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... An international research team including DESY scientists has observed ... The team reports in the journal Science ... lattices inside the nanodroplets. It is the first time ... in larger samples of what is known as superfluid ... exceeded our best expectations," says Andrey Vilesov of the ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... N.Y. , Aug. 21, 2014 ... launch of their Nutraceutical "TELO-20 for Dogs" with ... only Telomere-lengthening supplement in the world for dogs. ... of every chromosome in the body. A wealth ... leading experts in Telomere Science and Aging, including ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Scientists observe quantum vortices in cold helium droplets 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... commentary with Michael J. Cronin, Ph.D., J.D., an intellectual property ... look at the facts in the dispute over three important ... the history behind similar disputes - shows a strong likelihood ... all of its patent rights, even if some of its ...
... writing a series of articles on raising capital from investors. This ... of the time when raising equity capital, the offering terms are ... . When dealing with angel investors , it is ... ,Sometimes prospective angel investors will want to negotiate the initial term ...
... who once said everyone will be famous for 15 minutes, couldn't ... might have on his prediction. , ,With these tools, everyone can ... even that. It seems that 15 minutes is about all anyone ... of Silicon Valley. , ,I was reminded of this after ...
Cached Biology Technology:WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... Oct. 18-22, 2014 , WHERE: , San ... Diego, CA 92101 , WHAT: , Invited ... the latest research in human genetics. Examples of ... abstracts on rare genetic variants in health and ... for sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... and vegetables is a new, patented technology in which a ... "etch" information on produce, thereby eliminating the need for common ... a variety of fruits and vegetables and is being used ... been been approved in Asia, South Africa, Central and South ...
... of Illinois at Chicago have received $1 million from ... the relationship between "fat taxes" and food consumption, diet ... project was made available through the American Recovery and ... state tax rates associated with restaurants and with specific ...
... If a circadian rhythm is like an orchestra the united ... chemical may serve as the conductor, or at least as the ... ), the active ingredient in color safe bleach. Produced in all ... active and resting phases of living things, new research by USC ...
Cached Biology News:Laser etching safe alternative for labeling grapefruit 2UIC receives $1 million grant to study 'fat taxes,' diet, obesity 2Not just bleach: Hydrogen peroxide may tell time for living cells 2Not just bleach: Hydrogen peroxide may tell time for living cells 3
... the proven features of the pET, BacVector ... all of the benefits and versatility of ... The pTriEx vectors have been extensively tested ... all three expression systems. In each case, ...
... the first instrument engineered to match the ... by thousands of research centers worldwide. It ... which are ideally suited for high-speed temperature ... extremely high surface-area-to-volume ratio. ,By combining glass ...
... the cost-effective solution for entry level imaging ... research imaging tasks, MetaVue enables time lapse, ... analysis. Compatibility with MetaMorphs extensive and ... has the power to drive motorized microscopes, ...
... Clear amber to slightly cloudy ... 10 vials per set, each containing ... homogenized in the following proportions by ... A (mannide monooleate emulsifier), and 0.1% ...
Biology Products: